Opioid Risk Assessment Tool For Females
Assesses a woman’s likelihood of future opioid misuse based on personal history, psychiatric factors, and other validated risk predictors.
适用指征
Used before initiating chronic opioid therapy in women to estimate risk of future aberrant opioid behaviors and guide intensity of monitoring. Helps identify patients needing closer follow‑up, limited quantities, or additional safety strategies such as PDMP review and urine drug testing (NCCN Adult Cancer Pain Guidelines 1 [Level I evidence]). Assists clinicians in tailoring opioid prescribing and mitigating misuse risk.
洞见与注意事项
Begin by recognizing that risk scoring in women can overestimate risk when psychiatric symptoms or prior trauma are present and underestimate risk related to prescription exposure patterns. Most validation studies show variable sensitivity (0.37–0.89) and moderate specificity (0.68–0.83) in female cohorts 1 [Level II evidence]. Use scores only as screening adjuncts; confirm with clinical history, psychiatric comorbidity assessment, and review of prescription monitoring data.